Cintra Jane Rocha Duarte, Guerra Maximiliano Ribeiro, Bustamante-Teixeira Maria Teresa
Programa de Pós-graduação em Saúde Brasileira, NATES/Faculdade de Medicina, UFJF, Juiz de Fora, MG.
Rev Assoc Med Bras (1992). 2008 Jul-Aug;54(4):339-46. doi: 10.1590/s0104-42302008000400020.
Analyze the 5-year breast cancer specific-survival rate of women diagnosed with invasive non-metastatic disease, who as part of their primary treatment underwent surgery followed by adjuvant chemotherapy.
Four hundred twenty eight patients diagnosed between 1998 and 2000 were recruited from all oncology services of the municipality of Juiz de Fora, MG, Brasil. Survival time was counted from the date of the histopathological diagnosis and the date of death due to breast cancer was considered the adverse event. Women alive until December 2005, the final date of the follow-up, were censored. For those who interrupt treatment, censor date was the last follow-up in the medical records. Kaplan-Meier survival curves were estimated, with the differences assessed by the log-rank test.
Mean age was 51.2 years, and most (72.6%) were Caucasian. Clinical Stages II (47.4%) and III (38.6%) predominated. Breast cancer specific five-year survival rate was 82.0%. A worst survival was observed among women with disease diagnostic before menopause (p=0.02), with tumor size greater than 2.0 cm (p=0.05), with lymph node involvement (p=0,000), in a more advanced disease stage (p=0.000), on a full adjuvant chemotherapy regimen (p=0.03), and who used hormone therapy (p=0.05).
This research allowed identification of the profile and disease survival of breast cancer patients who used adjuvant chemotherapy. These results stimulated the adoption of intensive strategies by the local health authorities for disease control and prevention in this population, emphasizing the increasing need of breast cancer screening, mainly for women considered as of high risk and the availability of timely treatment for all cases diagnosed.
分析被诊断为浸润性非转移性疾病的女性患者的5年乳腺癌特异性生存率,这些患者在其初始治疗中接受了手术,随后进行辅助化疗。
从巴西米纳斯吉拉斯州茹伊斯迪福拉市的所有肿瘤科室招募了1998年至2000年间诊断的428名患者。生存时间从组织病理学诊断日期开始计算,因乳腺癌死亡的日期被视为不良事件。活到2005年12月(随访的最后日期)的女性被截尾。对于那些中断治疗的患者,截尾日期是病历中的最后一次随访。采用Kaplan-Meier生存曲线进行估计,差异通过对数秩检验进行评估。
平均年龄为51.2岁,大多数(72.6%)为白种人。临床分期II期(47.4%)和III期(38.6%)占主导。乳腺癌特异性5年生存率为82.0%。在绝经前诊断疾病的女性(p = 0.02)、肿瘤大小大于2.0 cm的女性(p = 0.05)、有淋巴结受累的女性(p = 0.000)、疾病分期更晚的女性(p = 0.000)、接受完整辅助化疗方案的女性(p = 0.03)以及使用激素治疗的女性(p = 0.05)中观察到较差的生存率。
本研究有助于确定使用辅助化疗的乳腺癌患者的特征和疾病生存率。这些结果促使当地卫生当局采取强化策略对该人群进行疾病控制和预防,强调了乳腺癌筛查需求的增加,主要针对被视为高危的女性,以及为所有确诊病例提供及时治疗的可及性。